Lymphomas are clinically heterogeneous disorders which are known to accumulate somatic mutations. For better diagnosis and prognosis of aggressive and indolent lymphomas, the molecular and genetic profiling of patients is invaluable. For example, SOCS1 and CDKN2A genetic mutations are known to have copy number loss in Diffuse large B cell lymphoma (BLBCL), and are therefore ideal molecular diagnostic markers. In a similar way, the EZH2 gene mutation status has been included in the modified FLIPI score for risk prognostication in follicular lymphomas.
To develop robust molecular and genetic companion diagnostic (CDx) tests, the use of reference material is imperative. Unlike synthetic alternatives, our engineered cancer cell line-based reference standards closely mimic patient samples. The Lymphoid Cancer genomic DNA panel has 10 SNVs and 3 CNVs relevant in major non-Hodgkin lymphomas. And because lymphomas are typically somatic, our panel contains allele frequencies as low as 5%. Further dilution to suit your assay cut-offs is possible with a matched negative control. All mutations are thoroughlly validated and manufactured under ISO 13485.
Format: Genomic DNA
Genes Covered: BRAF, CDKN2A, CXCR4, DNMT3A, EZH2, IDH2, MYD88, NRAS, RB1, SOCS1, STAT3, TET2, TP53
Allelic Frequencies: 5 - 50%
Buffer: Tris-EDTA (10mM Tris-HCl, 1mM EDTA), pH 8.1
|Gene||DNA sequence change||Amino acid change||COSMIC ID||Expected allelic frequency (%)|
Unit Size: 500ng
Allelic Frequency: Droplet Digital PCR™
DNA extraction: Maxwell platform
Quality: Agarose gel electrophoresis
Quantification: Spectrophotometry (A260)